Search - tctmd.com

Displaying 521 - 540 of 1857

Sort: Relevancy | Date

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

News Conference News ESC 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

August 28, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

News Conference News ESC 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

August 27, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Higher BP, Oxygen Targets No Help in Comatose OHCA Patients: BOX

News Conference News ESC 2022

Higher BP, Oxygen Targets No Help in Comatose OHCA Patients: BOX

August 27, 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

August 27, 2022

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

News Conference News ESC 2022

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

August 27, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

First Cardio-Oncology Guidelines From ESC Cover ‘Tremendous’ Territory

News Conference News ESC 2022

First Cardio-Oncology Guidelines From ESC Cover ‘Tremendous’ Territory

August 26, 2022

No Hints of Cognitive Defects With ARNIs in HFpEF

News Conference News ESC 2022

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

August 26, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection Open With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.” configuration options With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.”

News Conference News ESC 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection

August 26, 2022

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

News Conference News TVT 2022

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

Michael O'Riordan

June 13, 2022

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

News Conference News TVT 2022

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

Michael O'Riordan

June 10, 2022

More Support for Single Antiplatelet Therapy After TAVI

News Conference News TVT 2022

More Support for Single Antiplatelet Therapy After TAVI

Michael O'Riordan

June 10, 2022

No Stroke Reduction With Embolic Protection in TAVI, Two Studies Suggest

News Conference News TVT 2022

No Stroke Reduction With Embolic Protection in TAVI, Two Studies Suggest

Michael O'Riordan

June 09, 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.